2007
DOI: 10.1038/sj.eye.6702859
|View full text |Cite
|
Sign up to set email alerts
|

Vogt-Koyanagi-Harada disease in children

Abstract: Purpose To identify prognostic factors for outcome in children with Vogt-Koyanagi-Harada (VKH) disease. Methods All children 16 years and younger with acute uveitis associated with VKH disease treated between 1999 and 2006 were reviewed. Results Twenty-three children (46 eyes) were identified; 20 (87%) girls and three (13%) boys with a mean age at presentation of 12.572.4 years. Mean follow-up period was 48.6730.8 months. Visual acuity of 20/40 or better was achieved in 38 (82.6%) eyes. Eleven eyes developed a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
64
1
2

Year Published

2010
2010
2023
2023

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 54 publications
(70 citation statements)
references
References 16 publications
3
64
1
2
Order By: Relevance
“…6,10,12 This was confirmed by our study, in which ;60% of the 22 children with VKH disease were girls. Only one pediatric series had a greater total number of affected boys.…”
Section: Discussionsupporting
confidence: 93%
See 3 more Smart Citations
“…6,10,12 This was confirmed by our study, in which ;60% of the 22 children with VKH disease were girls. Only one pediatric series had a greater total number of affected boys.…”
Section: Discussionsupporting
confidence: 93%
“…The mean age of our patients was 12.6 years (range, 8 years to 16 years), which was similar to that found in previous reports in which the mean age ranged from 10 to 12.5 years. 10,11,12 The youngest reported patient was a 3-year-old Saudi Arabian girl. 33 Our youngest child was 8 years of age.…”
Section: Discussionmentioning
confidence: 97%
See 2 more Smart Citations
“…21,22 In children with VKH, the incidence of CNV is estimated to be as high as 70%. [23][24][25] CNV in VKH is known to have a poor visual prognosis. 26 Treated with systemic steroids for associated active ocular inflammation, no treatment for CNV.…”
Section: Etiologymentioning
confidence: 99%